| 000 | 01791 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250515004530.0 | ||
| 264 | 0 | _c20060612 | |
| 008 | 200606s 0 0 eng d | ||
| 022 | _a1592-8721 | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aQuach, Hang | |
| 245 | 0 | 0 |
_aComplete remission of hairy cell leukemia variant (HCL-v) complicated by red cell aplasia post treatment with rituximab. _h[electronic resource] |
| 260 |
_bHaematologica _cNov 2005 |
||
| 300 |
_aECR26 p. _bdigital |
||
| 500 | _aPublication Type: Case Reports; Journal Article | ||
| 650 | 0 | 4 |
_a2-Chloroadenosine _xadministration & dosage |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xtherapeutic use |
| 650 | 0 | 4 | _aAntibodies, Monoclonal, Murine-Derived |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use |
| 650 | 0 | 4 | _aBlood Transfusion |
| 650 | 0 | 4 | _aCombined Modality Therapy |
| 650 | 0 | 4 |
_aCyclophosphamide _xadministration & dosage |
| 650 | 0 | 4 |
_aDeoxyadenosines _xadministration & dosage |
| 650 | 0 | 4 | _aDisease Progression |
| 650 | 0 | 4 | _aDrug Resistance, Neoplasm |
| 650 | 0 | 4 | _aFatal Outcome |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aInterferon-alpha _xadministration & dosage |
| 650 | 0 | 4 |
_aLeukemia, Hairy Cell _xclassification |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aNeoplasms, Second Primary _xclassification |
| 650 | 0 | 4 |
_aPrednisolone _xadministration & dosage |
| 650 | 0 | 4 | _aRecurrence |
| 650 | 0 | 4 |
_aRed-Cell Aplasia, Pure _xdrug therapy |
| 650 | 0 | 4 | _aRemission Induction |
| 650 | 0 | 4 | _aRituximab |
| 650 | 0 | 4 | _aSplenectomy |
| 650 | 0 | 4 |
_aUrinary Bladder Neoplasms _xradiotherapy |
| 700 | 1 | _aJanuszewicz, Henry | |
| 700 | 1 | _aWesterman, David | |
| 773 | 0 |
_tHaematologica _gvol. 90 Suppl _gp. ECR26 |
|
| 999 |
_c15892405 _d15892405 |
||